Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

Local Anesthetic Treatment of Oral Pain in Patients With Mucositis

Phase 2

Completed

Conditions: Mucositis

Interventions: Drug: Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)
Drug: Bupivacaine

First Posted Date: 2014-09-30

Last Posted Date: 2016-08-16

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 70

Registration Number: NCT02252926

Locations: 🇩🇰
Department of Oncology, Herlev Hospital, Denmark, Herlev, Denmark
🇩🇰
Department of Oncology, Rigshospitalet, Copenhagen, Denmark

Analgesic Efficacy of Two Concentrations of Bupivacaine in Women in Labor

Phase 4

Completed

Conditions: Obstetric Pain

Interventions: Drug: bupivacaine

First Posted Date: 2014-09-18

Last Posted Date: 2016-05-27

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 114

Registration Number: NCT02244086

Locations: 🇲🇽
Hospital General Regional número 17, Instituto Mexicano del Seguro Social., Cancún, Quintana Roo, Mexico

Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: liposomal bupivacaine
Drug: Bupivacaine

First Posted Date: 2014-08-21

Last Posted Date: 2015-04-16

Lead Sponsor: Knight, Richard, M.D.

Target Recruit Count: 206

Registration Number: NCT02222129

Locations: 🇺🇸
Baptist Health System, San Antonio, Texas, United States
🇺🇸
Methodist Healthcare System, San Antonio, Texas, United States

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: EXPAREL

First Posted Date: 2014-08-06

Last Posted Date: 2021-07-06

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 60

Registration Number: NCT02210247

Locations: 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

Pain Relief After Colorectal Surgery: Spinal Combined With Painbuster® vs Painbuster® Alone.

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Procedure: Continuous infusion of local anaesthetic
Procedure: Spinal and infusion of local anaesthetic
Drug: Bupivacaine
Drug: Diamorphine
Device: A Painbuster® catheter
Device: 25G Whitacre needle

First Posted Date: 2014-08-06

Last Posted Date: 2016-09-14

Lead Sponsor: York Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 79

Registration Number: NCT02210260

Locations: 🇬🇧
Scarborough General Hospital, Scarborough, North Yorkshire, United Kingdom

Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy

Not Applicable

Completed

Conditions: Thyroid Neoplasms
Goiter, Nodular
Thyroid Nodule
Graves' Disease
Hyperparathyroidism

Interventions: Procedure: Superficial Cervical Plexus Block
Procedure: Local Wound Infiltration
Drug: Marcaine
Drug: 0.9% saline

First Posted Date: 2014-07-31

Last Posted Date: 2018-03-09

Lead Sponsor: University of Chicago

Target Recruit Count: 36

Registration Number: NCT02205801

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy

Phase 4

Completed

Conditions: Pain

Interventions: Drug: EXPAREL

First Posted Date: 2014-07-24

Last Posted Date: 2021-03-08

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 12

Registration Number: NCT02199574

Locations: 🇺🇸
Memorial Hermann - Memorial City Medical Center, Houston, Texas, United States
🇺🇸
Memorial Village Surgery Center, Houston, Texas, United States